(As, At, B, Ge, Si, Se, Te) Steroids
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
International Journal of Molecular Sciences Review Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level? Rola El Sayed 1 , Yolla Haibe 2, Ghid Amhaz 2, Youssef Bouferraa 2 and Ali Shamseddine 2,* 1 Global Health Institute, American University of Beirut, Beirut 11-0236, Lebanon; [email protected] 2 Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut 11-0236, Lebanon; [email protected] (Y.H.); [email protected] (G.A.); [email protected] (Y.B.) * Correspondence: [email protected]; Tel.: +961-1-350-000 (ext. 5390) Abstract: Immunotherapy has changed the treatment paradigm in multiple solid and hematologic malignancies. However, response remains limited in a significant number of cases, with tumors de- veloping innate or acquired resistance to checkpoint inhibition. Certain “hot” or “immune-sensitive” tumors become “cold” or “immune-resistant”, with resultant tumor growth and disease progres- sion. Multiple factors are at play both at the cellular and host levels. The tumor microenvironment (TME) contributes the most to immune-resistance, with nutrient deficiency, hypoxia, acidity and different secreted inflammatory markers, all contributing to modulation of immune-metabolism and reprogramming of immune cells towards pro- or anti-inflammatory phenotypes. Both the tumor and surrounding immune cells require high amounts of glucose, amino acids and fatty acids to fulfill their energy demands. Thus, both compete over one pool of nutrients that falls short on needs, obliging cells to resort to alternative adaptive metabolic mechanisms that take part in shaping their inflammatory phenotypes. Aerobic or anaerobic glycolysis, oxidative phosphorylation, tryptophan catabolism, glutaminolysis, fatty acid synthesis or fatty acid oxidation, etc. -
A Focus on Vinyl Selenones
molecules Review ReviewModern Synthetic Strategies with Organoselenium Reagents: Modern Synthetic Strategies with Organoselenium Reagents: AA FocusFocus onon VinylVinyl SelenonesSelenones Martina Palomba, Italo Franco Coelho Dias, Ornelio Rosati and Francesca Marini * Martina Palomba, Italo Franco Coelho Dias, Ornelio Rosati and Francesca Marini * Department of Pharmaceutical Sciences (Group of Catalysis, Synthesis and Organic Green Chemistry), UniversityGroup of Catalysis, of Perugia, Synthesis Via del andLiceo, Organic 06123 GreenPerugia, Chemistry, Italy; [email protected] Department of Pharmaceutical (M.P.); Sciences, italo.francocoelhodias@studeUniversity of Perugia, Via delnti.unipg.it Liceo, 06123 (I.F.C.D.); Perugia, [email protected] Italy; [email protected] (O.R.) (M.P.); *[email protected] Correspondence: [email protected] (I.F.C.D.); [email protected] (O.R.) * Correspondence: [email protected] Abstract: In recent years, vinyl selenones were rediscovered as useful building blocks for new syn- Abstract: In recent years, vinyl selenones were rediscovered as useful building blocks for new thetic transformations. This review will highlight these advances in the field of multiple-bond-form- synthetic transformations. This review will highlight these advances in the field of multiple-bond- ing reactions, one-pot synthesis of carbo- and heterocycles, enantioselective construction of densely forming reactions, one-pot synthesis of carbo- and heterocycles, enantioselective construction of functionalized molecules, and total synthesis of natural products. densely functionalized molecules, and total synthesis of natural products. Keywords: selenium; domino reactions; heterocycles; natural products; spiro compounds; annula- Keywords: selenium; domino reactions; heterocycles; natural products; spiro compounds; annula- tions; enantioselective synthesis; organocatalysis tions; enantioselective synthesis; organocatalysis Citation: Palomba, M.; Dias, I.F.C.; Rosati, O.; Marini, F. -
Modulating the Immune System Through Nanotechnology
Modulating the immune system through nanotechnology Tamara G. Dacobaa,b*, Ana Oliveraa,b*, Dolores Torresb, José Crecente- Campoa,b#, María José Alonsoa,b## aCenter for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain. bDepartment of Pharmacology, Pharmacy and Pharmaceutical Technology, School of Pharmacy, Campus Vida, Universidade de Santiago de Compostela, Santiago de Compostela 15782, Spain. *These authors contributed equally to this work. #Corresponding author e-mail address: [email protected] ##Corresponding author e-mail address: [email protected] 1 Abstract Nowadays, nanotechnology-based modulation of the immune system is presented as a cutting-edge strategy, which may lead to significant improvements in the treatment of severe diseases. In particular, efforts have been focused on the development of nanotechnology- based vaccines, which could be used for immunization or generation of tolerance. In this review, we highlight how different immune responses can be elicited by tuning nanosystems properties. In addition, we discuss specific formulation approaches designed for the development of anti-infectious and anti-autoimmune vaccines, as well as those intended to prevent the formation of antibodies against biologicals. Graphical abstract Keywords: nanotechnology; immune system; tolerance; stimulation; autoimmune disease; vaccine Highlights - Nanocarriers can be designed to target specific immune cells - Nanovaccines may help fighting diseases that are elusive to traditional vaccines - Nanocarriers can bias the immune response from humoral to cellular - Autoimmune disease treatments can be improved with nanotechnology-based approaches - The use of nanocarriers may help to avoid ADAs formation against biotherapeutics 2 1. Introduction The modulation of the immune system is the base of new and promising therapies for some of the most prevalent and/or severe diseases of our time, such as cancer, HIV, and diabetes. -
An Active Immunotherapy Combined with First-Line Weekly Paclitaxel In
An active immunotherapy combined with first-line weekly paclitaxel in metastatic breast cancer: first results of IMP321 (LAG-3Ig) as an antigen presenting cell activator in the AIPAC phase IIb trial Frédéric Triebel, CSO/CMO Precision: Breast Cancer March 7-8, 2017 Boston, MA. 1 ASX:PRR; NASDAQ:PBMD Notice: Forward Looking Statements The purpose of the presentation is to provide an update of the business of Prima BioMed Ltd ACN 009 237 889 (ASX:PRR; NASDAQ:PBMD). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima BioMed and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company’s filings to the ASX and SEC for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima BioMed’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. -
Tetrahedron Symposia-In-Print
Tetrahedron 74 (2018) 4875–4878 Tetrahedron Symposia-in-Print Tetrahedron Symposia-in-Print comprise collections of original research papers covering timely areas of organic chemistry. Each symposium is organized by a Symposium Editor who will invite authors, active in the selected field, to submit original articles covering cur- rent research, complete with experimental sections. These papers will be rapidly reviewed and processed for publication by the Symposium Editor under the usual refereeing system. Authors who have not already been invited, and who may have obtained recent significant results in the area of the announced symposium, may also submit contributions for Editorial consideration and possible inclusion. Before submitting such papers authors should send an abstract to the Symposium Editor for preliminary evaluation. Firm deadlines for receipt of papers will allow sufficient time for completion and presentation of ongoing work without loss of the freshness and timeliness of the research results. Symposia-in-Print—already published 1. Recent trends in organic photochemistry, Albert Padwa, Ed. Tetra- 22. Selectivity and synthetic applications of radical reactions, Bernd hedron 1981, 37, 3227–3420. Giese, Ed. Tetrahedron 1985, 41, 3887–4302. 2. New general synthetic methods, E. J. Corey, Ed. Tetrahedron 1981, 23. Recent aspects of organoselenium chemistry, Dennis Liotta, Ed. 37, 3871–4119. Tetrahedron 1985, 41,4727–4890. 3. Recent developments in polycyclopentanoid chemistry, Leo A. 24. Application of newer organometallic reagents to the total Paquette, Ed. Tetrahedron 1981, 37, 4357–4559. synthesis of natural products, Martin Semmelhack, Ed. 4. Biradicals, Josef Michl, Ed. Tetrahedron 1982, 38,733–867. Tetrahedron 1985, 41,5741–5900. 5. -
Molecular Advances in Pediatric Low-Grade Gliomas As a Model
Published OnlineFirst July 23, 2013; DOI: 10.1158/1078-0432.CCR-13-0662 Clinical Cancer CCR New Strategies Research New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model Eric Raabe1, Mark W. Kieran2, and Kenneth J. Cohen1 Abstract Pediatric low-grade gliomas (pLGG) account for more brain tumors in children than any other histologic subtype. While surgery, chemotherapy and radiation remain the mainstay of upfront treatment, recent advances in molecular interrogation of pLGG have shown a small number of recurring genetic mutations in these tumors that might be exploited therapeutically. Notable findings include abnormalities in the RAS/ MAP kinase pathway such as NF-1 loss or BRAF activation and mTOR activation. Recent identification of activating re-arrangements in c-MYB and MYBL1 in pediatric diffuse astrocytoma also provide candidates for therapeutic intervention. Targeting these molecularly identified pathways may allow for improved outcomes for patients as pediatric oncology moves into the era of biology-driven medicine. Clin Cancer Res; 19(17); 4553–8. Ó2013 AACR. Disclosure of Potential Conflicts of Interest M.W. Kieran is a consultant/advisory board member of Boehringer-Ingelheim, Incyte, Merck, Novartis, and Sanofi. No potential conflicts of interest were disclosed by the other authors. CME Staff Planners' Disclosures The members of the planning committee have no real or apparent conflict of interest to disclose. Learning Objective(s) Upon completion of this activity, the participant should have a better understanding of the molecular pathways that are active in pediatric low-grade gliomas and the biologic rationale underlying novel therapeutic strategies for children with these tumors. -
288 Part 348—External Analgesic Drug Products
Pt. 348 21 CFR Ch. I (4–1–11 Edition) should be used and any or all of the ad- Subpart C—Labeling ditional indications for sunscreen drug 348.50 Labeling of external analgesic drug products may be used. products. (c) Warnings. The labeling of the AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, product states, under the heading 360, 371. ‘‘Warnings,’’ the warning(s) for each in- gredient in the combination, as estab- SOURCE: 57 FR 27656, June 19, 1992, unless otherwise noted. lished in the warnings section of the applicable OTC drug monographs un- less otherwise stated in this paragraph Subpart A—General Provisions (c). § 348.1 Scope. (1) For combinations containing a skin (a) An over-the-counter external an- protectant and a sunscreen identified in algesic drug product in a form suitable §§ 347.20(d) and 352.20(b). The warnings for topical administration is generally for sunscreen drug products in recognized as safe and effective and is § 352.60(c) of this chapter are used. not misbranded if it meets each condi- (2) [Reserved] tion in this part and each general con- (d) Directions. The labeling of the dition established in § 330.1 of this product states, under the heading ‘‘Di- chapter. rections,’’ directions that conform to (b) References in this part to regu- the directions established for each in- latory sections of the Code of Federal gredient in the directions sections of Regulations are to chapter I of title 21 the applicable OTC drug monographs, unless otherwise noted. unless otherwise stated in this para- § 348.3 Definitions. -
Deadly Pediatric Poisons: Nine Common Agents That Kill at Low Doses Joshua B
Emerg Med Clin N Am 22 (2004) 1019–1050 Deadly pediatric poisons: nine common agents that kill at low doses Joshua B. Michael, MD, Matthew D. Sztajnkrycer, MD, PhD* Department of Emergency Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA Children are exposed more frequently to potentially toxic substances than any other age group [1]. According to data compiled by the American Association of Poison Control Centers (AAPCC), more than 1.3 million exposures involving children age 12 and younger were reported to poison control centers in 2001 [2]. Of these, more than 1 million (79%) involved children 3 years old or younger. The peak incidence for pediatric poisonings occurs in toddlers age 1 to 3 years, as does the peak incidence for hospitalization [3]. Most exposures in this age group are unintentional and reflect acquisition of developmental milestones and subsequent behaviors while exploring the environment. Children may be attracted to potentially toxic substances based on color or appearance of the agent or the container, mistakenly identifying it as a candy or beverage. Younger children are more willing to taste dangerous substances than older children and perform hand-mouth behaviors nearly 10 times an hour [4,5]. Physical environmental change plays a significant role in the epidemiology of accidental ingestion [6]. In approximately half of all accidental poisonings, the product either was in use at the time of ingestion or had been moved recently from its usual storage site. Ingestion characteristics differ significantly in toddler exposures com- pared with adolescent or adult exposures [7]. Most exposures are nontoxic because the intent is exploration rather than self-harm. -
Pathophysiology and Treatment of Pruritus in Elderly
International Journal of Molecular Sciences Review Pathophysiology and Treatment of Pruritus in Elderly Bo Young Chung † , Ji Young Um †, Jin Cheol Kim , Seok Young Kang , Chun Wook Park and Hye One Kim * Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym University, Seoul KS013, Korea; [email protected] (B.Y.C.); [email protected] (J.Y.U.); [email protected] (J.C.K.); [email protected] (S.Y.K.); [email protected] (C.W.P.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Pruritus is a relatively common symptom that anyone can experience at any point in their life and is more common in the elderly. Pruritus in elderly can be defined as chronic pruritus in a person over 65 years old. The pathophysiology of pruritus in elderly is still unclear, and the quality of life is reduced. Generally, itch can be clinically classified into six types: Itch caused by systemic diseases, itch caused by skin diseases, neuropathic pruritus, psychogenic pruritus, pruritus with multiple factors, and from unknown causes. Senile pruritus can be defined as a chronic pruritus of unknown origin in elderly people. Various neuronal mediators, signaling mechanisms at neuronal terminals, central and peripheral neurotransmission pathways, and neuronal sensitizations are included in the processes causing itch. A variety of therapies are used and several novel drugs are being developed to relieve itch, including systemic and topical treatments. Keywords: elderly; ion channel; itch; neurotransmission pathophysiology of itch; pruritogen; senile pruritus; treatment of itch 1. Introduction Citation: Chung, B.Y.; Um, J.Y.; Kim, Pruritus is a relatively common symptom that anyone can experience at any point in J.C.; Kang, S.Y.; Park, C.W.; Kim, H.O. -
Anti-Depressant-Like Effect of Curculigoside Isolated from Curculigo Orchioides Gaertn Root
Wang et al Tropical Journal of Pharmaceutical Research October 2016; 15 (10): 2165-2172 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v15i10.15 Original Research Article Anti-depressant-like effect of curculigoside isolated from Curculigo orchioides Gaertn root Jing Wang1*, Xiao-Li Zhao2 and Lan Gao3 1Neurology Department, Shanxi Provincial People’s Hospital, Taiyuan 030012, 2Neurology Department, The First Hospital of Xi’an City, Xi’an 710002, Shanxi, 3Beijing Huilongguan Hospital, Beijing 100096, China *For correspondence: Email: [email protected]; Tel/Fax: +86-0351-4960171 Received: 5 March 2016 Revised accepted: 9 September 2016 Abstract Purpose: To investigate the anti-depressant-like activity of curculigoside from Curculigo orchioides Gaertn and its underlying mechanism(s). Methods: Antidepressant-like activity was determined in mice through forced swimming test (FST), tail suspending test (TST), and open field test (OFT). Mechanism of action was investigated by measuring levels of dopamine (DA), norepinephrine (NE), and 5-hydroxytryptamine (5-HT) in chronic mild stress (CMS) rats using high-performance liquid chromatography-electron capture detector (HPLC-ECD). Western blotting was used to investigate the effect of curculigoside on the expression of brain-derived neurotrophic factor (BDNF) protein in rats. Results: In FST and TST, treatment of mice with curculigoside (10, 20, 40 mg/kg, p.o.) significantly reduced immobility time, which was, however, unaffected by locomotor activity when assessed in the OFT. The treatment led to significant increases in DA, NE and 5-HT, and up-regulation of BDNF protein expression in the hippocampus of the CMS rats. -
5 -7 -9 -11 Organoselenium Chemistry.' Redox Chemistry Of
J. Am. Chem. SOC.1987, 109, 5549-5551 5549 <- <- 1;1P B solid state or solution above 183K solution below183K Figure 1. Evolution of the (PP3)Rh fragment on going from (PP,)RhH to (PP3)Rh+. within 2 h. The compound 6 in turn adds H2 (1 atm) to reform II 2. Finally, 2 quickly exchanges H, with C2H4to give [(PP3)- Rh(C2H,)](S0,CF,)" (7) whose 31PNMR spectrum with an AB,X spin system closely resembles that of 2. This result is reasonable because of the analogy between the binding of H2 and olefins to metals. It has been previously argued that both steric and electronic factors must be finely "tuned" on a metal fragment to permit the formation of an q2-H2adductla The geometric change of the (PP,)Rh fragment from C,, to C,, symmetry (Figure 1) is ac- companied by a certain variation of the fragmental frontier or- bitals. Likely the key to understand the mechanism of the present cis-dihydride - q2-dihydrogen interconversion may be found in the orbital control operated by the (PP,)Rh fragment. Supplementary Material Available: Analytical data and ex- perimental (80 MHz) and computed 'H NMR spectrum of [(PP,)Rh(HD)] (O,CCF,) (2 pages). Ordering information is given on any current masthead page. (10) The compound, which is a nonconductor in CH3CN and C2HSN02, exists in solution as a 1:l mixture of two isomers most likely due to the triflate ligand (IR 1310 cm-' (s), v (SO) of coordinated triflate). 31P(1HJNMR (CD3COCD,, 298 K) AB2CX system, isomer 1: 6 PA 112.33, 6 PB52.06, 6 Pc 24.70; isomer 2: 6 PA 104.15, 6 PB 52.06, 6 PA 112.33, 6 PB52.06, 6 Pc 2 52 24.70; isomer 2: 6 PA 104.15, 6 PB 52.06, 6 Pc 16.52 (JpApB= 27.0 Hz, JpApC = 14.2 HZ, JpBpc = 34.3 HZ, JpARh = 119.7 HZ, JpB~h= 132.1 HZ, JpC~h =140.9 Hz). -
Matrine Inhibits Itching by Lowering the Activity of Calcium Channel
www.nature.com/scientificreports OPEN Matrine inhibits itching by lowering the activity of calcium channel Xiao Geng1, Hao Shi1, Fan Ye1, Han Du2, Linnan Qian1, Leying Gu1, Guanyi Wu1, Chan Zhu1, Yan Yang1, Changming Wang1, Yuan Zhou1, Guang Yu 1, Qin Liu3, Xinzhong Dong 4,5, 1 1 Received: 12 January 2018 Lei Yu & Zongxiang Tang Accepted: 22 June 2018 Sophorae Flavescentis Radix (SFR) is a medicinal herb with many functions that are involved in anti- Published: xx xx xxxx infammation, antinociception, and anticancer. SFR is also used to treat a variety of itching diseases. Matrine (MT) is one of the main constituents in SFR and also has the efect of relieving itching, but the antipruritic mechanism is still unclear. Here, we investigated the efect of MT on anti-pruritus. In acute and chronic itch models, MT signifcantly inhibited the scratching behavior not only in acute itching induced by histamine (His), chloroquine (CQ) and compound 48/80 with a dose-depended manner, but also in the chronic pruritus models of atopic dermatitis (AD) and acetone-ether-water (AEW) in mice. Furthermore, MT could be detected in the blood after intraperitoneal injection (i.p.) and subcutaneous injection (s.c.). Finally, electrophysiological and calcium imaging results showed that MT inhibited the excitatory synaptic transmission from dorsal root ganglion (DRG) to the dorsal horn of the spinal cord by suppressing the presynaptic N-type calcium channel. Taken together, we believe that MT is a novel drug candidate in treating pruritus diseases, especially for histamine-independent and chronic pruritus, which might be attributed to inhibition of the presynaptic N-type calcium channel.